Monte Rosa Therapeutics

Senior Research Associate, Cellular Immunology ( 6 Month Contract)

Monte Rosa Therapeutics  •  Boston, MA (Onsite)  •  12 days ago
Apply
AI can make mistakes so check important info. Chat history is never stored.

Job Description

Monte Rosa Therapeutics is seeking an energetic and highly motivated Contractor located in Boston to support the development and characterization of novel molecular glue degraders for the treatment of inflammatory diseases. As part of the Immunology and Preclinical Pharmacology team, this role will broadly support multiple immunology and inflammation (I&I) projects/programs from early lead optimization through clinical-stage.

The ideal candidate is an experienced experimentalist with a strong background in I&I and a demonstrated ability to work collaboratively to achieve team/company goals.

Responsibilities

  • Design, optimize and execute experiments using a variety of primary immune cells and tissues isolated from human, mouse or cynomolgus monkey (including PBMCs, monocyte-derived macrophages, whole blood, synovial fluid, peritoneal fluid, etc.)
  • Routine profiling of compounds using Meso Scale Discovery (MSD), ELISA, Western blot, Simple Western (Jess), flow cytometry, qPCR assays
  • Ex vivo mouse tissue processing (spleen, bone marrow, lymph node, etc.)
  • Maintain timely and detailed notes using electronic lab notebook

Qualifications

  • MS or PhD equivalent in Immunology or Cell Biology with 3+ years of hands-on experience in I&I drug discovery research in a pharmaceutical setting
  • Extensive experience handling whole blood, primary immune cells and tissue (preferably including clinical samples)
  • Expert in protein detection/quantitation methodology (e.g., MSD, ELISA, Western blotting, Jess)
  • Flow cytometry expertise is preferred
  • Highly proficient with Microsoft Excel, GraphPad Prism (FlowJo is preferred)
Monte Rosa Therapeutics

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN™ discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs.

Industry
Biotech & Life Sciences
Company Size
201-500 employees
Headquarters
Boston, Massachusetts
Year Founded
Unknown
Social Media